Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gilead Sciences, in collaboration with Merck Sharp & Dohme LLC, is currently conducting a Phase 3 clinical study titled ‘An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03).’ The study aims to evaluate the efficacy of pembrolizumab combined with sacituzumab govitecan compared to pembrolizumab alone in improving progression-free survival and overall survival in patients with metastatic non-small cell lung cancer with a PD-L1 tumor proportion score of 50% or higher.
The interventions being tested are pembrolizumab, a known immunotherapy drug, and sacituzumab govitecan, a targeted cancer therapy. The combination is intended to enhance treatment efficacy for patients with advanced lung cancer.
This interventional study is designed as a randomized, parallel assignment with no masking, focusing on treatment as the primary purpose. Participants are allocated to either the combination therapy group or the monotherapy group to compare outcomes.
The study began on February 6, 2023, and is currently recruiting participants. The primary completion date is yet to be determined, with the last update submitted on August 19, 2025. These dates are crucial for tracking the study’s progress and potential market entry of the combination therapy.
The outcome of this study could significantly impact Gilead Sciences’ stock performance and investor sentiment, as successful results may enhance their oncology portfolio. This development is particularly relevant in the competitive landscape of cancer therapies, where advancements can lead to substantial market shifts.
The study is ongoing, with further details available on the ClinicalTrials portal.